Deals

OIS Index Q2 2019

OIS Index Posts Modest Gain for Q2; Ophthalmic Market Leader Alcon Joins Index

By Michael Lachman | July 10, 2019

The OIS Index of ophthalmic stocks posted a modest positive return of +0.8% during the second quarter of 2019. The index outperformed the NASDAQ Biotechnology…

Read More
A Closer Look at AbbVie-Allergan Deal and Where Eye Care Fits In

A Closer Look at AbbVie-Allergan Deal and Where Eye Care Fits In

By Keith Croes | June 26, 2019

NEW YORK – In what’s been called “a transformative move for both companies,” AbbVie has agreed to buy Allergan in a deal valued at $63…

Read More
Why Ophthalmology Bulls Keep Running

Why Equity and M&A Markets in Ophthalmology Are Poised for a Great Run

By Keith Croes | June 13, 2019

SAN DIEGO – Although the 10-year bull market is bound to end one of these days, the trend in ophthalmology and healthcare in general is…

Read More
A Dozen Takeaways from OIS@ASCRS 2019

A Dozen Takeaways from OIS@ASCRS 2019

By Steve Lenier | May 8, 2019

Last week’s OIS@ASCRS 2019 saw a record number of registrants, and the 650 attendees were treated to a wealth of information from the presenting companies,…

Read More
How OIS@ASCRS 2019 Breaks the Mold

OIS@ASCRS Features New Sessions, Companies

By Steve Lenier | April 24, 2019

OIS@ASCRS 2019 will convene next Thursday, May 2, preceding the American Society of Cataract and Refractive Surgery annual meeting in San Diego. This year’s OIS@ASCRS…

Read More
OIS Index

OIS Index Delivers Stellar First-Quarter 2019 Performance

By Michael Lachman | April 3, 2019

The OIS Index of ophthalmic stocks solidly outperformed its market benchmarks in the first quarter of 2019, gaining 37.1%. During Q1, the overall US stock…

Read More
Biogen Jumps Back into Ophthalmology Gene Therapy with Nightstar Acquisition

Biogen Jumps Back into Ophthalmology Gene Therapy with Nightstar Acquisition

By Rich Kirkner | March 13, 2019

It didn’t take Biogen long to jump back into ophthalmology after announcing its intention in December 2018 to terminate a collaborative agreement with Applied Genetic…

Read More
How Glaucoma Device Companies Raise Funding to Navigate ‘Death Valley’

How Glaucoma Device Companies Raise Funding to Navigate ‘Death Valley’

By Heather Johnson | March 6, 2019

SAN FRANCISCO – At the Glaucoma 360 New Horizons Forum here, Emmett Cunningham, Jr., MD, PhD, moderating a panel on financing for emerging glaucoma device…

Read More
10 Takeaways from Roche-Spark Deal

10 Takeaways from Roche’s $4.8 Billion Offer to Acquire Spark Therapeutics

By Rich Kirkner | February 27, 2019

Here are 10 things to know about Roche’s $4.8 billion bid to acquire Spark Therapeutics. Roche’s $114.5-a-share offer is a 122% premium over the closing…

Read More
The Upside of the Optometric Channel

Corporate Leaders Explain the Upside of the Optometric Channel

By Karen Blum | February 27, 2019

NEW ORLEANS – Optometry has become a source of big business for ophthalmic companies over the past decade, with about 40 to 60% of sales…

Read More
OIS Index Follows the Stock Market Lower in December

OIS Index Follows the Stock Market Lower in December

By Michael Lachman | January 10, 2019

The OIS Index declined 11% in December, marking the fourth month in a row in which ophthalmic stocks lost value. For the month, the overall…

Read More
Alcon Executives Lay Out a Road Map for after the Spin-off

Alcon Executives Lay Out a Road Map for after the Spin-off

By Karen Blum | December 18, 2018

With a management team experienced in healthcare and ophthalmology, and market trends like aging increasing the need for ophthalmic care and a rich pipeline of…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.